PL3774789T3 - Związki ukierunkowane na BRM i związane z nimi sposoby stosowania - Google Patents

Związki ukierunkowane na BRM i związane z nimi sposoby stosowania

Info

Publication number
PL3774789T3
PL3774789T3 PL19717685.2T PL19717685T PL3774789T3 PL 3774789 T3 PL3774789 T3 PL 3774789T3 PL 19717685 T PL19717685 T PL 19717685T PL 3774789 T3 PL3774789 T3 PL 3774789T3
Authority
PL
Poland
Prior art keywords
brm
associated methods
targeted compounds
targeted
compounds
Prior art date
Application number
PL19717685.2T
Other languages
English (en)
Inventor
Andrew P. Crew
Jing Wang
Michael Berlin
Peter Dragovich
Huifen Chen
Leanna STABEN
Original Assignee
Arvinas Operations, Inc.
Genentech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arvinas Operations, Inc., Genentech, Inc. filed Critical Arvinas Operations, Inc.
Publication of PL3774789T3 publication Critical patent/PL3774789T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
PL19717685.2T 2018-04-01 2019-04-01 Związki ukierunkowane na BRM i związane z nimi sposoby stosowania PL3774789T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862651186P 2018-04-01 2018-04-01
US201962797754P 2019-01-28 2019-01-28
PCT/US2019/025254 WO2019195201A1 (en) 2018-04-01 2019-04-01 Brm targeting compounds and associated methods of use

Publications (1)

Publication Number Publication Date
PL3774789T3 true PL3774789T3 (pl) 2025-08-18

Family

ID=66175525

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19717685.2T PL3774789T3 (pl) 2018-04-01 2019-04-01 Związki ukierunkowane na BRM i związane z nimi sposoby stosowania

Country Status (28)

Country Link
US (2) US20190300521A1 (pl)
EP (2) EP3774789B1 (pl)
JP (3) JP7721270B2 (pl)
KR (2) KR102697733B1 (pl)
CN (2) CN112166114B (pl)
AU (3) AU2019249849C1 (pl)
BR (1) BR112020020196A2 (pl)
CA (1) CA3094305A1 (pl)
CL (1) CL2020002546A1 (pl)
CO (1) CO2020013762A2 (pl)
CR (1) CR20200527A (pl)
DK (1) DK3774789T3 (pl)
ES (1) ES3027032T3 (pl)
FI (1) FI3774789T3 (pl)
HR (1) HRP20250617T1 (pl)
HU (1) HUE071391T2 (pl)
IL (1) IL277677A (pl)
LT (1) LT3774789T (pl)
MX (2) MX2020010368A (pl)
MY (1) MY198308A (pl)
PE (1) PE20212108A1 (pl)
PH (1) PH12020500663A1 (pl)
PL (1) PL3774789T3 (pl)
PT (1) PT3774789T (pl)
RS (1) RS66841B1 (pl)
SG (1) SG11202008898UA (pl)
SI (1) SI3774789T1 (pl)
WO (1) WO2019195201A1 (pl)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US12539292B2 (en) 2018-04-01 2026-02-03 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use
EP3774789B1 (en) * 2018-04-01 2025-03-05 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
JP7720698B2 (ja) 2018-04-04 2025-08-08 アルビナス・オペレーションズ・インコーポレイテッド タンパク質分解の調節因子および関連する使用方法
CN112771038B (zh) * 2018-04-26 2024-09-24 奥里吉恩发现科技有限公司 作为smarca2/4降解剂的哒嗪衍生物
CA3093405C (en) 2018-04-30 2025-06-17 Dana-Farber Cancer Institute, Inc. POLYBROMO-1 SMALL MOLECULE DEGRADING AGENTS (PBRM1)
EP3817822A4 (en) 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
WO2020041331A1 (en) 2018-08-20 2020-02-27 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
AU2019365238A1 (en) 2018-10-24 2021-05-13 F. Hoffmann-La Roche Ag Conjugated chemical inducers of degradation and methods of use
CN113453679B (zh) 2018-12-20 2025-07-08 C4医药公司 靶向蛋白降解
WO2020160192A1 (en) 2019-01-29 2020-08-06 Foghorn Therapeutics Inc. Compounds and uses thereof
CN113677664B (zh) 2019-04-12 2025-04-04 C4医药公司 Ikaros和aiolos的三环降解物
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
WO2021011913A1 (en) 2019-07-17 2021-01-21 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
WO2021067606A1 (en) * 2019-10-01 2021-04-08 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
AU2020366135B2 (en) * 2019-10-16 2024-12-12 Proxygen Gmbh Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
CN115397821B (zh) 2019-10-17 2024-09-03 阿尔维纳斯运营股份有限公司 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子
WO2021086785A1 (en) * 2019-10-28 2021-05-06 F. Hoffmann-La Roche Ag Bifunctional compounds
EP4051674A1 (en) * 2019-10-29 2022-09-07 F. Hoffmann-La Roche AG Bifunctional compounds for the treatment of cancer
CN115297931A (zh) 2019-12-23 2022-11-04 凯麦拉医疗公司 Smarca降解剂和其用途
AU2021205326A1 (en) * 2020-01-10 2022-07-21 Amgen Inc. SMARCA2-VHL degraders
AU2021213258B2 (en) * 2020-01-29 2024-05-02 Foghorn Therapeutics Inc. Compounds and uses thereof
WO2021155100A1 (en) 2020-01-29 2021-08-05 Foghorn Therapeutics Inc. Compounds and uses thereof
BR112022014968A2 (pt) 2020-01-29 2022-09-20 Foghorn Therapeutics Inc Composto, composição farmacêutica e métodos de inibição do nível de brd9 em uma célula, de inibição da atividade de brd9 em uma célula, de tratamento de um distúrbio, de tratamento de um câncer em um sujeito em necessidade e de tratamento de infecção em um sujeito em necessidade
US20230096160A1 (en) * 2020-02-12 2023-03-30 Dana-Farber Cancer Institute, Inc. Compounds, compositions, and methods for protein degradation
MX2022010952A (es) 2020-03-05 2022-10-07 C4 Therapeutics Inc Compuestos para la degradacion dirigida de brd9.
AU2021289730A1 (en) * 2020-06-09 2023-01-19 Prelude Therapeutics, Incorporated BRM targeting compounds and associated methods of use
BR112023001143A2 (pt) 2020-07-21 2023-02-14 Genentech Inc Conjugado, composto, composição farmacêutica, métodos para tratar uma doença e reduzir o nível de uma proteína brm alvo em um indivíduo
US11787800B2 (en) 2020-07-29 2023-10-17 Foghorn Therapeutics Inc. BRD9 degraders and uses thereof
US20240018134A1 (en) * 2020-08-04 2024-01-18 Aurigene Discovery Technologies Limited 6-Substituted Pyridazine Compounds as SMARCA2 and/or SMARCA4 Degraders
WO2022032026A1 (en) 2020-08-05 2022-02-10 C4 Therapeutics, Inc. Compounds for targeted degradation of ret
US12448389B2 (en) 2020-11-06 2025-10-21 Prelude Therapeutics Incorporated BRM targeting compounds and associated methods of use
US20240343724A1 (en) * 2020-12-09 2024-10-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
US20250109138A1 (en) * 2020-12-09 2025-04-03 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
EP4277901A1 (en) 2021-01-13 2023-11-22 Monte Rosa Therapeutics, Inc. Isoindolinone compounds
TW202241855A (zh) * 2021-01-27 2022-11-01 美商富曼西公司 用於防治無脊椎有害生物之唑類化合物
CR20230516A (es) 2021-04-16 2024-01-23 Arvinas Operations Inc Moduladores de la proteólisis bcl6 y métodos de uso asociados
KR20240017814A (ko) 2021-05-05 2024-02-08 바이오젠 엠에이 인코포레이티드 브루톤 티로신 키나제의 분해를 표적으로 하는 화합물
PE20242362A1 (es) * 2021-05-10 2024-12-16 Foghorn Therapeutics Inc Compuestos y usos de estos
WO2023283263A1 (en) 2021-07-06 2023-01-12 Foghorn Therapeutics Inc. Citrate salt, pharmaceutical compositions, and methods of making and using the same
EP4366834A1 (en) 2021-07-07 2024-05-15 Biogen MA Inc. Compounds for targeting degradation of irak4 proteins
US20240343733A1 (en) 2021-07-07 2024-10-17 Biogen Ma Inc. Compounds for targeting degradation of irak4 proteins
WO2023287787A1 (en) * 2021-07-13 2023-01-19 Prelude Therapeutics, Incorporated Brm targeting compounds and associated methods of use
WO2023093728A1 (zh) * 2021-11-23 2023-06-01 江苏先声药业有限公司 Brm选择性降解剂化合物及其应用
US20250064945A1 (en) 2021-11-24 2025-02-27 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use
CN118679160A (zh) 2021-11-24 2024-09-20 阿维纳斯运营公司 Brm靶向化合物和相关的使用方法
KR102676912B1 (ko) * 2021-12-14 2024-06-24 (주)프레이저테라퓨틱스 폴리유비퀴틴화에 의한 표적 단백질 또는 폴리펩티드의 분해용 신규 화합물
WO2023129506A1 (en) * 2021-12-28 2023-07-06 Board Of Regents, The University Of Texas System Potent and selective smarca2 degrading chimeric molecules as cancer therapeutics
AR128330A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpo y métodos de estos
AR128331A1 (es) 2022-01-26 2024-04-17 Genentech Inc Inductores químicos de degradación conjugados con anticuerpos y métodos de estos
JP2025525339A (ja) 2022-06-16 2025-08-05 プレリュード・セラピューティクス・インコーポレイテッド ビキチンリガーゼ結合部分を有するｋａｔ６標的化合物
EP4549431A1 (en) * 2022-06-30 2025-05-07 Gan & Lee Pharmaceuticals Co., Ltd. Compound functioning as smarca2/4 inhibitor and use thereof
CN115353468B (zh) * 2022-08-19 2023-06-30 安阳工学院 一种对甲苯磺酰氧基取代低聚乙二醇丙酸叔丁酯的制备方法
AU2023382631A1 (en) 2022-11-15 2025-05-29 Prelude Therapeutics Incorporated Brm targeting compounds and associated methods of use
AU2024212035A1 (en) 2023-01-26 2025-08-14 Arvinas Operations, Inc. Cereblon-based kras degrading protacs ans uses related thereto
CN120752233A (zh) * 2023-02-28 2025-10-03 上海海雁医药科技有限公司 取代的三环衍生物及其药物组合物和用途
AR132905A1 (es) 2023-06-08 2025-08-06 Nurix Therapeutics Inc Degradadores selectivos bifuncionales de smarca2 y sus usos terapéuticos
WO2024256574A1 (en) * 2023-06-13 2024-12-19 Crossfire Oncology Holding B.V. Process for preparing macrocyclic btk inhibitors
AU2024305423A1 (en) 2023-06-14 2026-01-22 Astrazeneca Ab Smarca2 degraders and uses thereof
TW202515566A (zh) 2023-06-14 2025-04-16 瑞典商阿斯特捷利康公司 Ｓｍａｒｃａ２降解劑及其用途
AU2024303022A1 (en) * 2023-06-16 2026-01-08 Plexium, Inc. Compounds and pharmaceutical compositions that degrade swi/snf-related matrix-associated actin-dependent regulator of chromatin subfamily a
WO2025094065A1 (en) * 2023-11-01 2025-05-08 Aurigene Oncology Limited Amino-substituted pyridazine compounds as smarca2 and/or smarca4 degraders
WO2025101942A1 (en) 2023-11-10 2025-05-15 Prelude Therapeutics Incorporated Kat6 targeting compounds
WO2025106637A1 (en) * 2023-11-16 2025-05-22 Foghorn Therapeutics Inc. Cinnoline derivatives useful as baf modulators
WO2025131111A1 (zh) * 2023-12-22 2025-06-26 上海海雁医药科技有限公司 双环稠杂芳环衍生物及其药物组合物和用途
US20250276074A1 (en) 2024-03-01 2025-09-04 Prelude Therapeutics Incorporated Brm and brg1 targeting antibody-drug conjugates and methods of use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
TWI440981B (zh) 2003-12-03 2014-06-11 尼康股份有限公司 Exposure apparatus, exposure method, and device manufacturing method
EP3608317A1 (en) 2012-01-12 2020-02-12 Yale University Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
WO2015160845A2 (en) * 2014-04-14 2015-10-22 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
US9694084B2 (en) * 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
JP6815318B2 (ja) * 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
HK1245791A1 (zh) 2015-01-20 2018-08-31 阿尔维纳斯运营股份有限公司 用於雄激素受体的靶向降解的化合物和方法
MA41598A (fr) 2015-02-25 2018-01-02 Constellation Pharmaceuticals Inc Composés thérapeutiques de pyridazine et leurs utilisations
HK1249058A1 (zh) 2015-03-18 2018-10-26 Arvinas, Inc. 用於增强靶向蛋白质降解的化合物和方法
CA2988430A1 (en) * 2015-07-10 2017-01-19 Arvinas, Inc. Mdm2-based modulators of proteolysis and associated methods of use
KR20180029061A (ko) * 2015-07-13 2018-03-19 아비나스 인코포레이티드 단백질 분해의 알라닌계 조절인자 및 관련된 이용 방법
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
EP3370715A4 (en) 2015-11-02 2019-05-15 Yale University CHIMERIC COMPOUNDS PROVIDED AGAINST PROTEOLYSIS AND METHOD FOR THE PRODUCTION AND USE THEREOF
CA3050309A1 (en) 2017-01-31 2018-08-09 Arvinas Operations, Inc. Cereblon ligands and bifunctional compounds comprising the same
CN107698657A (zh) 2017-09-26 2018-02-16 中国药科大学 基于vhl配体和bet抑制剂诱导bet降解的双功能分子及其制备和应用
EP3774789B1 (en) * 2018-04-01 2025-03-05 Arvinas Operations, Inc. Brm targeting compounds and associated methods of use

Also Published As

Publication number Publication date
AU2022204042A1 (en) 2022-06-30
RU2020135754A (ru) 2022-05-04
CN112166114A (zh) 2021-01-01
KR20240130153A (ko) 2024-08-28
CL2020002546A1 (es) 2021-01-29
EP4537905A3 (en) 2025-06-25
CN112166114B (zh) 2024-11-19
EP4537905A2 (en) 2025-04-16
HRP20250617T1 (hr) 2025-07-18
KR20210005037A (ko) 2021-01-13
JP7721270B2 (ja) 2025-08-12
DK3774789T3 (da) 2025-06-10
KR102697733B1 (ko) 2024-08-26
US20240076295A1 (en) 2024-03-07
US20190300521A1 (en) 2019-10-03
SI3774789T1 (sl) 2025-07-31
EP3774789B1 (en) 2025-03-05
ES3027032T3 (en) 2025-06-12
AU2019249849B2 (en) 2022-03-17
BR112020020196A2 (pt) 2021-01-26
AU2019249849C1 (en) 2022-09-29
JP2023071767A (ja) 2023-05-23
SG11202008898UA (en) 2020-10-29
FI3774789T3 (fi) 2025-06-17
JP2025143253A (ja) 2025-10-01
PT3774789T (pt) 2025-05-28
AU2024203058A1 (en) 2024-05-30
PH12020500663A1 (en) 2021-06-07
MX2020010368A (es) 2021-01-08
CO2020013762A2 (es) 2021-01-18
NZ767872A (en) 2024-04-26
EP3774789A1 (en) 2021-02-17
MY198308A (en) 2023-08-22
AU2019249849A1 (en) 2020-10-01
WO2019195201A1 (en) 2019-10-10
RU2020135754A3 (pl) 2022-05-04
MX2024000329A (es) 2024-01-25
LT3774789T (lt) 2025-06-25
RS66841B1 (sr) 2025-06-30
CN120504668A (zh) 2025-08-19
PE20212108A1 (es) 2021-11-04
JP2021520350A (ja) 2021-08-19
HUE071391T2 (hu) 2025-08-28
IL277677A (en) 2020-11-30
CA3094305A1 (en) 2019-10-10
CR20200527A (es) 2021-04-09

Similar Documents

Publication Publication Date Title
PL3774789T3 (pl) Związki ukierunkowane na BRM i związane z nimi sposoby stosowania
HUE065695T2 (hu) Szövet életképesség mérése
EP3645100C0 (en) INSTRUMENT INSERTION COMPENSATION
HRP20251095T1 (hr) Neoantigeni i metode njihove uporabe
EP3506836C0 (en) EXTENSION FOR SURGICAL INSTRUMENT
PT3548033T (pt) Compostos e respectivos métodos de utilização
BR112018000129A2 (pt) oxiesteróis e seus métodos de utilização
EP3826638A4 (en) ELAGOLIX SODIUM COMPOSITIONS AND RELATED METHODS
IL283782A (en) Anellosomes and methods of use
PL3262183T3 (pl) Test na obecność i wrażliwość bakterii na środki przeciwdrobnoustrojowe
IL257386A (en) Mechanism of resistance to bet bromodomain inhibitors
EP3834750C0 (en) MEDICAL INSTRUMENT
IL272200A (en) Isochroman compounds and uses thereof
EP3609409C0 (en) SURGICAL SIMULATION SYSTEM
UA40089S (uk) Кальян
EP3630150A4 (en) PURIFIED ANTHELMINTIC COMPOSITIONS AND RELATED PROCEDURES
EP3412273A4 (en) ROOT CHANNEL TREATMENT AND ROOT CHANNEL TREATMENT MATERIAL
EP3849664C0 (en) PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF
EP3603687A4 (en) MEDICAL DEVICE
EP3747479A4 (en) MEDICAL INSTRUMENT
EP3761891A4 (en) KNEE INSTRUMENTS AND METHODS
IL262137B (en) Optical configurations for optical field mappings for back-scanned and line-scanned imagers
EP3415524A4 (en) INHIBITOR OF α-SYNNUCLEINE EXPRESSION
EP3897152C0 (en) NEMATOCIDE COMPOSITIONS
DK3796979T3 (da) Mir-181-hæmmere og anvendelser deraf